Editorials

How should we decide on the best regimen for eradicating Helicobacter pylori?

BMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.7005.581 (Published 02 September 1995) Cite this as: BMJ 1995;311:581
  1. Vincenzo Savarino,
  2. Sergio Vigneri
  1. Associate professor of gastroenterology Departimento di Medicina Interna, Universita di Genova, 16132 Genoa, Italy
  2. Associate professor of gastroenterology Departimento di Medicina Interna, Universita di Genova, 16132 Genoa, Italy

    The search is still on for the simplest, shortest, most effective, and best tolerated regimen

    The rediscovery of Helicobacter pylori has revolutionised our therapeutic approach to peptic ulcer. Although the pathogenetic link between infection with H pylori and the formation of ulcers is still unclear, eradicating the organism dramatically reduces relapses of ulcers. This has prompted many investigators to find the best eradicating regimen.

    Treatments against the bacterium have evolved rapidly over the past few years, even though most current information comes from small clinical trials, often published only in abstract form. Despite this limitation rates of eradication have continually improved, and nowadays we should adopt only eradicating regimens that achieve at least 90% success.1

    As the bacterium responds poorly to monotherapy, combinations of two, three, or four drugs have been studied intensively. Until recently a 14 day course of a bismuth compound, metronidazole, and either amoxycillin or …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe